ftdp-17-genetics-mapt-mutations

ftdp-17-genetics-mapt-mutations

Overview

Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17) is caused by autosomal dominant mutations in the [MAPT gene](/genes/mapt) (Microtubule-Associated Protein Tau). Over 50 pathogenic mutations have been identified, making FTDP-17 one of the most genetically heterogeneous neurodegenerative disorders. This page focuses on the molecular mechanisms by which these mutations cause disease.

ftdp-17-genetics-mapt-mutations

Overview

Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17) is caused by autosomal dominant mutations in the [MAPT gene](/genes/mapt) (Microtubule-Associated Protein Tau). Over 50 pathogenic mutations have been identified, making FTDP-17 one of the most genetically heterogeneous neurodegenerative disorders. This page focuses on the molecular mechanisms by which these mutations cause disease.

MAPT Gene Structure and Alternative Splicing

Exon 10 Splicing Regulation

The MAPT gene contains 16 exons, with exon 10 being critically important because it encodes the second microtubule-binding repeat. Alternative splicing of exon 10 determines whether the resulting tau protein contains 3 repeats (3R) or 4 repeats (4R) of the microtubule-binding domain:

• 3R tau: Exon 10 excluded — results from inclusion of exon 10a (11 amino acids)
• 4R tau: Exon 10 included — standard protein

Splicing Regulatory Elements

Exon 10 splicing is regulated by multiple elements:

• Exonic splicing enhancers (ESEs): Bound by SR proteins (serine/arginine-rich proteins)
• Exonic splicing silencers (ESSs): Bound by hnRNPs
• Intronic branch points and polypyrimidine tracts

Pathogenic MAPT Mutations

Mutation Categories

FTDP-17 mutations can be divided into two major functional categories:

1. Missense Mutations (Coding Region)

Missense mutations alter the amino acid sequence of tau protein, affecting its biophysical properties:

| Mutation | Location | Effect on Tau Function |
|----------|----------|------------------------|
| P301L | Exon 10 | Severely reduced microtubule binding, increased aggregation |
| P301S | Exon 10 | Reduced microtubule binding, increased aggregation |
| P301T | Exon 10 | Reduced microtubule binding |
| V337M | Exon 12 | Altered microtubule binding, promotes aggregation |
| G389R | Exon 13 | Reduced microtubule binding |
| R406W | Exon 13 | Altered binding, affects phosphorylation |

The P301L mutation is the most studied and most common FTDP-17 mutation. It reduces microtubule binding affinity by approximately 4-fold and dramatically increases the propensity for aggregation into paired helical filaments.

2. Splicing Mutations (Intronic/Exonic)

Splicing mutations affect the alternative splicing of exon 10, leading to increased production of 4R tau isoforms:

| Mutation | Location | Effect |
|----------|----------|--------|
| +3 | Intron 10 | Increased 4R tau (most common splicing mutation) |
| +12 | Intron 10 | Increased 4R tau |
| +14 | Intron 10 | Increased 4R tau |
| +16 | Intron 10 | Increased 4R tau |
| S305I | Exon 10 | Increased 4R tau |
| S305N | Exon 10 | Increased 4R tau |
| ΔN296 | Exon 10 | Alters splicing, 4R predominant |

The intron 10 mutations (+3, +12, +14, +16) are particularly important because they disrupt a stem-loop structure that normally regulates exon 10 splicing.

Molecular Mechanisms of Neurodegeneration

Loss of Microtubule Binding Function

Tau's primary physiological function is to stabilize microtubules. Mutations that reduce microtubule binding lead to:

The P301L mutation reduces tau's ability to promote microtubule assembly by approximately 75%, leading to significant disruption of axonal transport.

Gain of Toxic Aggregation Function

Mutations that promote aggregation lead to:

Alteration of the 3R/4R Tau Ratio

Splicing mutations that increase 4R tau production lead to:

Dysregulation of Signaling Pathways

Mutant tau can dysregulate multiple signaling pathways:

• MAPK activation: Tau promotes nuclear translocation of MAPK, affecting gene expression[@alonso2004]
• GSK3β dysregulation: Altered tau function affects this major tau kinase
• cAMP/PKA signaling: Altered through tau's interaction with various effectors

Penetrance and Phenotypic Variation

Age of Onset

FTDP-17 typically presents between 40-60 years of age, though onset can vary:

• P301L: 45-55 years
• P301S: 50-60 years
• +3 intronic: 40-55 years
• V337M: 50-60 years
• R406W: 55-65 years

Phenotypic Variability

Even within families carrying the same mutation, phenotype can vary significantly. This suggests:

• Modifier genes: Other genetic variants influence phenotype
• Environmental factors: Lifestyle and environmental exposures modify expression
• Stochastic factors: Random variation in neuronal vulnerability

Animal Models of FTDP-17

Transgenic Mouse Models

Several mouse models have been developed to study FTDP-17 mechanisms:

| Model | Mutation | Key Features |
|-------|----------|---------------|
| JNPL3 | P301L | Age-dependent NFT formation, motor deficits |
| rTg4510 | P301L (inducicible) | Reversible tau expression, cognitive decline |
| P301S | P301S | Rapid onset, severe pathology |

These models demonstrate that mutant tau is sufficient to cause neurodegeneration and cognitive deficits.

Therapeutic Implications

Targeting Mutant Tau

Understanding the molecular mechanisms has informed therapeutic strategies:

Biomarker Development

Cerebrospinal fluid biomarkers for FTDP-17 include:

• Total tau (elevated)
• Phosphorylated tau (elevated at specific sites)
• 4R tau isoforms (increased relative to 3R)[@ingason2012]

Cross-References

• [FTDP-17 disease page](/diseases/ftdp-17)
• [MAPT gene](/genes/mapt)
• [Tau protein](/proteins/tau)
• [4R-Tauopathy mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [Tau filament structures](/mechanisms/tau-filament-structures-4r-tauopathies)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ftdp-17-genetics-mapt-mutations discovered through SciDEX knowledge graph analysis: